XML 15 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Consolidated Statements of Income (Unaudited) (USD $)
In Thousands, except Per Share data, unless otherwise specified
 3 Months Ended 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Net sales $ 505,066 $ 498,697 $ 1,530,059 $ 1,495,396
Cost of goods sold 220,850 224,927 674,330 654,784
Gross profit 284,216 273,770 855,729 840,612
Selling, general and administrative expense 202,238 160,134 583,486 492,913
Research and development expense 52,920 47,795 155,104 150,637
Segment profit (loss) 29,058 65,841 117,139 197,062
Interest expense 31,611 11,901 54,252 37,498
Foreign exchange losses, net 3,330 448 5,723 3,508
Other (income) expense, net (667) (1,511) (10,711) (14,692)
Income before income taxes (5,216) 55,003 67,875 170,748
Provision for income taxes (1,883) (12,383) (20,200) (48,375)
Net income including noncontrolling interests (7,099) 42,620 47,675 122,373
Net loss (income) attributable to noncontrolling interests 0 13 (21) (148)
Net income attributable to Bio-Rad $ (7,099) $ 42,633 $ 47,654 $ 122,225
Basic earnings per share:        
Net income per share basic attributable to Bio-Rad $ (0.25) $ 1.51 $ 1.67 $ 4.33
Weighted average common shares - basic 28,603 28,312 28,545 28,255
Diluted earnings per share:        
Net income per share diluted attributable to Bio-Rad $ (0.25) $ 1.49 $ 1.65 $ 4.27
Weighted average common shares - diluted 28,603 28,645 28,870 28,609